Department of Microbiology, Tumor and Cell Biology (MTC), Karolinska Institute, Box 280, SE-171 77, Stockholm, Sweden.
Vaccine. 2012 Sep 14;30(42):6093-8. doi: 10.1016/j.vaccine.2012.07.041. Epub 2012 Aug 1.
Epstein-Barr virus (EBV) infection is an established risk factor for B-cell lymphomas in Human Immunodeficiency virus (HIV)-1 infected patients. A disturbed EBV-host relationship is seen in patient groups with a high risk for EBV-associated lymphomas. We have analysed this relationship by measuring EBV-DNA in the blood of HIV-1 carriers.
EBV-DNA load in B-cells was monitored by PCR in non- or insufficiently antiretroviral treated and rgp160-vaccinated HIV-patients.
Both asymptomatic HIV-infected and AIDS-patients showed a 25-40-fold increase in the number of B cell associated EBV-DNA copies compared to healthy controls. Patients included in a vaccine trial with recombinant HIV gp160 showed a 5-fold increase of EBV load compared to non-immunised patients and a 50-fold increase compared to healthy controls. There was no difference whether they received vaccine or "placebo". Vaccinated patients with a history of symptomatic primary HIV-1 infection (PHI) had a 280-fold increase in median EBV load compared to healthy controls, thus suggesting a synergistic effect between the vaccination and PHI, which hypothetically could affect lymphoma risk.
We recommend analysis of EBV-load and long term follow up of lymphoma risk in all therapeutic HIV-1 vaccination trials.
EB 病毒（EBV）感染是人类免疫缺陷病毒（HIV-1）感染患者 B 细胞淋巴瘤的既定危险因素。在具有 EBV 相关淋巴瘤高风险的患者群体中，观察到 EBV-宿主关系紊乱。我们通过测量 HIV-1 携带者血液中的 EBV-DNA 来分析这种关系。
通过 PCR 监测非或未充分接受抗逆转录病毒治疗和 rgp160 疫苗接种的 HIV 患者的 B 细胞中 EBV-DNA 载量。
与健康对照组相比，无症状 HIV 感染者和 AIDS 患者的 B 细胞相关 EBV-DNA 拷贝数增加了 25-40 倍。接受重组 HIV gp160 疫苗试验的患者与未免疫患者相比 EBV 负荷增加了 5 倍，与健康对照组相比增加了 50 倍。他们是否接种疫苗或“安慰剂”没有差异。有症状原发性 HIV-1 感染（PHI）病史的接种疫苗患者的 EBV 负荷中位数比健康对照组增加了 280 倍，这表明疫苗接种和 PHI 之间存在协同作用，这可能会影响淋巴瘤的风险。
我们建议在所有治疗性 HIV-1 疫苗接种试验中分析 EBV 负荷并长期随访淋巴瘤风险。
